Susan Hasty, Publisher
Table of Contents . . . April 9th, 2001
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Hepatitis Weekly | Other Publications
Pathogenesis - Hepatitis B Virus X Protein Mediates Toxin-Induced Liver Cancer
Therapy (Hepatitis C) - Mild and Chronic Hepatitis Patients Respond Alike To Interferon
Drug Development - Compounds Demonstrate Strong HBV-Specific Antiviral Activity In Vitro
Drug Development - Peptides Blocking HCV Genome Translation May Have Therapeutic Value
Adverse Drug Effects - Thalidomide Sparks Hepatitis Onset In Leukemia Patient
Epidemiology - Teen Injection Drug Users In Dublin, Ireland, Practice High-Risk Behaviors
Epstein-Barr Virus - Grafts In EBV-Infected Patients Rejected Due To Immunosuppression
Hemophilia - Pasteurized Clotting Factor Effective, Virus-Free
Liver Cancer - Aflatoxin Exposure Increases Disease Risk Among Population In Asia
Liver Cancer - Dual Procedures Increase Survival When Portal Vein Tumor Thrombus Is Present
Liver Cancer - Survival Rates Low After Surgery For Hepatocellular Carcinoma Recurrence
Liver Transplantation - Study Examines Outcomes Of Using Older Cadaveric Donors
Occupational Risk - Hepatitis C Rate Among Health Care Workers In Lebanon Is Low
Therapy (HCV) - Clinical Trial For Albumin Fusion Protein Drug To Start
Therapy (HCV) - U.S. FDA Assigns HCV Drug Priority Review Status
Therapy (Hepatitis B) - Infection, Interferon Interrupt Growth In Children With Chronic Hepatitis
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.